Triazolam, sold under the brand name Halcion, is banned in the United Kingdom and several other countries because of reports linking it to amnesia, paranoia, hallucinations, and violent behavior at rates higher than other sleeping pills in the same drug class. Britain revoked its license in 1991, and other nations followed with outright bans or severe restrictions. The drug remains available by prescription in the United States, though with a much lower recommended dose than was originally marketed and a label that carries explicit warnings about its psychiatric side effects.
The Side Effects That Triggered Bans
Triazolam is a benzodiazepine, the same family of drugs that includes medications commonly prescribed for anxiety and sleep. What set triazolam apart was a pattern of unusual psychiatric reactions. Reports accumulated through the 1980s of patients experiencing memory blackouts, paranoid thinking, confusion, aggression, sleepwalking, and hallucinations, sometimes at standard therapeutic doses. These weren’t just occasional oddities. The FDA’s own label acknowledges that anterograde amnesia (the inability to form new memories after taking the drug) “may occur at a higher rate with triazolam than with other benzodiazepine hypnotics.”
In clinical data reviewed during safety assessments, the risk ratio for amnesia with triazolam reached as high as 56 to 1 compared to placebo in some analyses. Other reported reactions included delusions, mania, depersonalization (feeling detached from yourself), and what the label calls “paradoxical reactions,” where instead of calming you down, the drug causes restlessness, irritability, and agitation. These effects could be deeply disorienting and, in some cases, dangerous.
Why Triazolam Acts Differently
The key lies in how quickly triazolam leaves your body. It has a plasma half-life of just 1.5 to 5.5 hours, making it one of the shortest-acting benzodiazepines available. That rapid clearance is a double-edged sword. On one hand, it means less morning grogginess than a longer-acting sleeping pill. On the other, the drug’s effects wear off so fast that the brain can experience a kind of mini-withdrawal between doses.
The FDA label describes this directly: because the drug is eliminated so quickly, a “relative deficiency” develops at the brain’s receptor sites before the next dose. This can cause two specific problems after several weeks of nightly use. First, people start waking up during the last third of the night as the drug wears off. Second, increased daytime anxiety can appear after roughly 10 days of continuous use. This rebound effect makes the original insomnia feel worse, which can drive people to take higher doses, amplifying the risk of the psychiatric side effects that made the drug controversial in the first place.
The UK Ban and Suppressed Data
Britain pulled triazolam’s license in 1991 after mounting evidence of serious side effects. The decision became even more contentious when legal proceedings revealed that the drug’s manufacturer, Upjohn (now part of Pfizer), had known about safety problems for nearly two decades. One clinical trial showed an 11% dropout rate among people taking triazolam, compared with 3.7% on placebo and 2.9% on another sleep medication. That data was available to the company as early as 1974 but, as alleged in British legal proceedings, was deliberately withheld from regulators.
New Zealand also discontinued oral triazolam, removing it from the national pharmaceutical schedule and advising prescribers not to start new patients on the drug. Several other countries imposed restrictions ranging from outright bans to strict limits on dosing and duration of use.
Why It’s Still Available in the U.S.
The FDA conducted its own safety review in the early 1990s and reached a different conclusion than Britain. The agency found that when triazolam was compared head-to-head with temazepam (another benzodiazepine sleep aid) in studies involving more than 4,000 patients per group, the incidence of serious psychiatric events like hallucinations, amnesia, and suicide attempts was similar between the two drugs: 12 events in the triazolam group versus 11 in the temazepam group. The FDA also noted that all benzodiazepines carry dose-related risks of memory impairment, not just triazolam.
Rather than banning the drug, the FDA chose to keep it available at lower doses with stronger label warnings. The side effect profile at the 0.25 mg dose showed amnesia-related events in about 7% of patients, compared to 4% on placebo. At 0.5 mg, that figure climbed to 10%. The higher doses that had been common in other countries were linked to greater risk, and the FDA’s position was essentially that triazolam could be used safely if the dose was kept low and the duration short.
Dose-Dependent Risk
The pattern in the data is consistent: higher doses produce dramatically more problems. At the lowest dose (0.125 mg), amnesia rates were actually lower than placebo in some analyses, at around 2%. At 0.25 mg, the rate roughly doubled. At 0.5 mg, it more than doubled again. Older adults were especially vulnerable, with expected rates of amnesia-related events reaching as high as 14.3% in geriatric subjects.
This dose sensitivity helps explain the divergence in regulatory decisions across countries. In markets where triazolam was commonly prescribed at 0.5 mg or higher, the side effect profile was considerably worse. Countries that saw the most alarming reports tended to be those where higher doses were standard practice. The FDA’s approach of capping the recommended dose and restricting use to short periods (typically 7 to 10 days) was an attempt to preserve access while narrowing the window of risk.
Drug Interactions That Compound the Danger
Triazolam is broken down in the liver by a specific enzyme system. Anything that slows that enzyme down will cause triazolam to build up in the bloodstream, effectively turning a low dose into a much higher one. Common medications that can do this include certain antifungal drugs, some antibiotics, and HIV medications. Even grapefruit juice can interfere with the same enzyme pathway. Because triazolam already has such a narrow margin between a therapeutic dose and a problematic one, these interactions can push someone into the danger zone unexpectedly. This pharmacological vulnerability is another reason several countries decided the risks weren’t worth managing and opted for a ban instead.